Bulletin
Investor Alert

Aug. 7, 2020, 3:29 p.m. EDT

New informative study On Ovarian Cancer Drug Market 2020|F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Aug 07, 2020 (CDN Newswire via Comtex) -- A detailed survey of upstream raw materials, recent industry dynamics, and downstream demand are also covered in the Ovarian Cancer Drug Market report. This latest market report has been studied for reporting major advancements, emerging growth status, competitive landscape analysis, segmentation and so on. This business research report showcases an overall mapping of the industry vendors and the analysis of the competitive landscape. It also provides a whole assessment of the global market in order to generate strong growth tactics so that the global players attain a powerful position in the international industry.

Ovarian cancer drug market is rise gradually to an estimated value of USD 5.6 Billion by 2026 substantial CAGR of 20.1% in the forecast period of 2019-2026. Rising incidence of ovarian cancer, growing geriatric population and robust drug pipeline for treating ovarian cancer are the key factors for enhancing the market growth.

Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ovarian-cancer-drug-market

A few techniques we use are:

  • Customer analysis

  • Competitor analysis

  • Risk analysis

  • Product research

  • Advertising research

  • E-mail survey and many more…

Few of the major competitors currently working in the ovarian cancer market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Exelixis, Inc., DelMar Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., Oasmia Pharmaceutical AB, TESARO, Inc., Amgen, Inc., and among others.

Market Drivers

  • Increase in prevalence rate of ovarian cancer worldwide

  • Rising awareness about treatment and technological advancement is driving the growth of market

  • Increase in the rate of R&D initiatives is driving ovarian cancer therapeutics market

Market Restraints

  • High cost involved in the treatment

  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market

  • Lack of awareness among the patient and physician about ovarian treatment

Segmentation: Global Ovarian Cancer Drug Market

By Type

  • Epithelial Ovarian Cancer

  • Germ Cell Ovarian Tumor

  • Sex Cord Stromal Tomours

  • Borderline Ovarian Tumour

  • Others

By Drug Type

  • Alkylating Agents

  • Mitotic Inhibitors

  • Carboplatin

  • Cisplatin

  • Docetaxel

  • Paclitaxel

  • Vegfr Inhibitor

  • Parp Inhibitors

  • Niraparib

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.